(Q33635029)

28 July 2017

1 reference

title

Current and emerging treatment options for Graves' hyperthyroidism (English)

1 reference

28 July 2017

Prakash Abraham

1

1 reference

28 July 2017

Shamasunder Acharya

series ordinal

2

1 reference

28 July 2017

publication date

2 February 2010

1 reference

Therapeutics and Clinical Risk Management

28 July 2017

published in

1 reference

28 July 2017

volume

6

1 reference

28 July 2017

page(s)

29-40

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

28 July 2017

copyright license

start time

1 December 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Radioiodine treatment for pediatric Graves' disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Clinical practice. Graves' disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Surgical treatment of Graves' disease: evidence-based approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

A systematic review of drug therapy for Graves' hyperthyroidism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Epidemiology and prevention of Graves' ophthalmopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Hyperthyroidism and cardiovascular morbidity and mortality

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

The use of antithyroid drugs in pregnancy and lactation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Radioiodine and the treatment of hyperthyroidism: the early history

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

The management of hyperthyroidism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Short‐term treatment of Graves' disease with methimazole in high versus low doses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Single daily dose methimazole treatment of hyperthyroidism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Antithyroid Drugs and Graves' Disease: A Prospective Randomized Evaluation of the Efficacy of Treatment Duration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Differences and Similarities in the Diagnosis and Treatment of Graves' Disease in Europe, Japan, and The United States

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Rituximab in relapsing Graves' disease, a phase II study.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Thyroid function and mortality in patients treated for hyperthyroidism

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Arterial embolization: a novel approach to thyroid ablative therapy for Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Rectal administration of propylthiouracil in the treatment of Graves' disease

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2817786

Treatment of hyperthyroidism with a small single daily dose of methimazole

30 October 2018

1 reference

12 December 2020

Increased Cardiovascular and Cancer Mortality after Radioiodine Treatment for Hyperthyroidism

1 reference

12 December 2020

Radiation alarm at an airport after radioiodine therapy

1 reference

12 December 2020

Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism

1 reference

12 December 2020

Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis

1 reference

12 December 2020

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug

1 reference

12 December 2020

Intrathyroidal concentrations of methimazole in patients with Graves' disease

1 reference

12 December 2020

[Treatment of Basedow disease with synthetic antithyroid drugs. Evaluation of the dose on the efficacy of the long term treatment]

1 reference

12 December 2020

Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease

1 reference

12 December 2020

Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose

1 reference

12 December 2020

Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism

1 reference

12 December 2020

Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion

1 reference

12 December 2020

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

1 reference

12 December 2020

Methimazole: an alternative route of administration

1 reference

12 December 2020

[Recurrence of Graves-Basedow disease: the influence of treatment schedule]

1 reference

12 December 2020

Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?

1 reference

12 December 2020

Hashimoto encephalopathy following iodine 131 (131 I) radiotherapy of Graves disease

1 reference

12 December 2020

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

1 reference

12 December 2020

Cancer mortality after iodine-131 therapy for hyperthyroidism

1 reference

12 December 2020

Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism

1 reference

12 December 2020

Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs

1 reference

12 December 2020

Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse

1 reference

12 December 2020

Treatment of hyperthyroidism with a combination of methimazole and cholestyramine

1 reference

12 December 2020

Carbimazole and the Autoimmune Response in Graves' Disease

1 reference

12 December 2020

Long-Term Follow-up Study of Compensated Low-Dose131I Therapy for Graves' Disease

1 reference

12 December 2020

Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs

1 reference

12 December 2020

A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients

1 reference

12 December 2020

Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease

1 reference

12 December 2020

The efficacy of thyroidectomy for Graves' disease: A meta-analysis

1 reference

12 December 2020

The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center

1 reference

12 December 2020

Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study

1 reference

12 December 2020

Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm

1 reference

12 December 2020

Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients

1 reference

12 December 2020

Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?

1 reference

12 December 2020

COMPARISON OF METHIMAZOLE, METHIMAZOLE AND SODIUM IPODATE, AND METHIMAZOLE AND SATURATED SOLUTION OF POTASSIUM IODIDE IN THE EARLY TREATMENT OF HYPERTHYROID GRAVES’DISEASE

1 reference

12 December 2020

Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study

1 reference

12 December 2020

Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids

1 reference

12 December 2020

Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment

1 reference

12 December 2020

The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals

1 reference

12 December 2020

Identifiers

0 references

1 reference

28 July 2017

1 reference